For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Histologically confirmed metastatic non-small cell lung cancer (NSCLC) of squamous
             (SQ) or non-squamous (NSQ) histology with Stage IV A/B (as defined by the 8th
             International Association for the Study of Lung Cancer Classification) or recurrent
             disease following multi-modal therapy for locally advanced disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of less than or
             equal to 1 at screening and confirmed prior to randomization

          -  Measurable disease by computed tomography (CT) or magnetic resonance resources (MRI)
             per response evaluation criteria in solid tumor version 1.1 (RECIST 1.1) criteria

          -  No prior systemic anti-cancer treatment (including epidermal growth factor receptor
             (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors) given as primary therapy for
             advanced or metastatic disease

        Exclusion Criteria:

          -  Participants with EGFR, ALK, ROS-1, or known B-rapidly accelerated fibrosarcoma
             proto-oncogene (BRAF V600E) mutations that are sensitive to available targeted therapy

          -  Untreated CNS metastases

          -  Leptomeningeal metastases (carcinomatous meningitis)

          -  Concurrent malignancy requiring treatment or history of prior malignancy active within
             2 years prior to randomization (ie, participants with a history of prior malignancy
             are eligible if treatment was completed at least 2 years before randomization and the
             participant has no evidence of disease)

          -  Prior treatment with an anti-programmed cell death protein 1 (PD-1), anti-programmed
             death-ligand 1 (PD-L1), anti-programmed death-ligand 2 (PD-L2), or anti-cytotoxic
             T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug
             specifically targeting T-cell co-stimulation or checkpoint pathways

        Other protocol-defined inclusion/exclusion criteria apply